Merck Sees FDA OK for Six-Week Keytruda Dosing in Six Indications

Date : 07/09/2019 @ 11:27AM
Source : Dow Jones News
Stock : Merck and Co Inc (MRK)
Quote : 89.365  0.645 (0.73%) @ 7:57PM

Merck Sees FDA OK for Six-Week Keytruda Dosing in Six Indications

Merck (NYSE:MRK)
Historical Stock Chart

6 Months : From Jun 2019 to Dec 2019

Click Here for more Merck Charts.

By Colin Kellaher


Merck & Co. (MRK) on Tuesday said the U.S. Food and Drug Administration accepted for review applications to include an every-six-weeks dosing schedule for its cancer drug Keytruda in six indications.

The Kenilworth, N.J., drug maker said it filed the six supplemental biologics license applications to update the dosing frequency for Keytruda in melanoma, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, gastric cancer, hepatocellular carcinoma and Merkel cell carcinoma.

Merck said the agency has set a target action date of Feb. 18, 2020.

Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, is currently approved for dosing every three weeks.


Write to Colin Kellaher at


(END) Dow Jones Newswires

July 09, 2019 07:12 ET (11:12 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest MRK Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.